Compare Abeona Therapeutics Inc (ABEO) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares Ultra Semiconductors — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while ProShares Ultra Semiconductors trades at $88.33. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| ABEO | USD | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $113.53 |
52-Week Low | $4.17 | $37.63 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
USD stock trades at $90.36, up 3.26% with a bearish technical signal from moving averages. The company announced a $0.14 dividend payable June 30, 2026. Recent news highlights institutional interest with JPMorgan Chase increasing its stake by 325% in Q3 2026. Technical indicators show neutral oscillators but bearish momentum with key support at $85 and resistance at $93.
The stock faces headwinds from bearish technical momentum despite recent price gains. Institutional accumulation and dividend payments provide support, but the overall technical picture suggests caution. Semiconductor sector volatility remains a key risk factor for this leveraged ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
